You are here

Seminar: Cancer from Bench to Bedside

Dr. Jessica Winter, The Ohio State University
Tuesday, November 28, 2017, 12:00 pm to 1:00 pm
E100 Scott Lab
201 W. 19th Ave.
Columbus, OH 43210

Abstract

One of the greatest difficulties in developing effective cancer therapies is disease heterogeneity. Molecular medicines, such as trastuzumab and erlotinib, have made tremendous inroads in therapy. However, the expression of the markers that these medicines target can vary from patient to patient and even from cell to cell. It is increasingly clear that new technologies are required to evaluate cancer chemical pathways to identify new drug targets and to match patients to those therapies (i.e., personalized medicine). Using examples from our work, I will describe a journey of cancer therapeutic development from discovery to implementation, with a focus on the unique contributions of engineers to the process.

We begin our journey with discovery, and I will describe our work to identify new cancer therapeutics that target cues in the tumor microenvironment. In particular, we are developing models that mimic chemical, mechanical, and physical features that may be found in glioma brain cancers. I will describe models that mimic increased tumor interstitial fluid pressure that we are using to identify potential mechanisms of glioma resistance to cell death.

The next step on our journey examines the challenges of drug delivery, particularly to the brain, which is limited by the blood-brain-barrier. I will describe polymeric drug carriers that our group has designed to deliver hydrophobic drugs to brain tumors. I will also describe methods to manufacture these carriers at high throughput, as would be required for clinical application.

Our journey ends by matching patients to available therapies, and I will describe our work to develop diagnostic technologies for leukemia and lymphoma. We are developing quantum dot imaging probes for clinical translation. We have also developed methods of manufacturing these probes at high throughput manufacturing methods, and I will describe our commercialization efforts through Core Quantum Technologies, a company founded by myself and former students, to get these diagnostic technologies to market.

About the Speaker

Jessica Winter is a Professor in the William G. Lowrie Department of Chemical and Biomolecular Engineering and the Department of Biomedical Engineering, Associate Director of the MRSEC Center for Emergent Materials at the Ohio State University, and Past Chair of the Nanoscale Science and Engineering Forum of the American Institute of Chemical Engineers. She received her PhD in Chemical Engineering from the University of Texas at Austin in 2004, and completed a postdoctoral fellowship at the Center for Innovative Visual Rehabilitation at the Boston VA Hospital in 2006. Her research interests include nanoparticles for cancer imaging, diagnostics, and drug delivery; and cell migration in the brain tumor microenvironment. She is a co-founder and Chief Scientific Officer of Core Quantum Technologies, a company commercializing nanoparticle reagents for leukemia diagnostics. She was named TechColumbus Innovator of the Year, Columbus Business First 40 under 40, and Columbus Business First 20 People to Know in Technology. In addition, she has received the American Chemical Society Rising Star Award and the Golden Mouse Trap Engineering Rising Star Award; she was named to Top 25 STEM professors in Ohio; and is a fellow of the AAAS, AIMBE, and senior member of the IEEE and AIChE.

Hosted by Professor Jonathan Song